Disney: $20M for the Tech, $180M for the People. Plus a Fifth Eye Drop | Tech Arcade Podcast

Disney is paying $20 million for a licence to Character.AI's technology in bankruptcy court, while budgeting about $180 million over three years for the staff it hired from the company. Then: the FDA has approved Opus Genetics' Ryzumvi for presbyopia, the age-related blur in close-up vision, joining a category of eye drops that has struggled to sell.

Full story: https://www.techarcade.io/disney-spent-20-million-on-character-ai-s-tech-and-180-million-on-the-people-who-built-it/

Full story: https://www.techarcade.io/the-fda-just-cleared-a-fifth-eye-drop-for-aging-eyes-and-the-first-four-barely-sold/

Sources

https://www.businesswire.com/news/home/20261012656385/en/Character.ai-Initiates-Voluntary-Chapter-11-Proceeding-to-Facilitate-Value-Maximizing-Sale-Process

https://ppc.land/disney-pays-20m-for-character-ais-ip-and-180m-for-its-staff/

https://ppc.land/disney-budgets-180m-for-character-ai-staff-20m-for-the-bankrupt-company/

https://www.benzinga.com/markets/tech/26/10/62427403/disney-60-million-character-ai-employees-ai-strategy

https://www.emarketer.com/content/disney-could-turn-character-ai-failed-chatbot-business-internal-asset

https://www.pymnts.com/artificial-intelligence-2/2024/google-reportedly-spent-2-7-billion-to-rehire-character-ai-founder/

https://www.globenewswire.com/news-release/2026/10/16/3382714/0/en/opus-genetics-announces-fda-approval-of-phentolamine-ophthalmic-solution-0-75-for-the-treatment-of-presbyopia.html

https://reviewob.com/is-the-presbyopia-drop-market-ready/

Where sources differ: the filing's three-year staff estimate (about $180M) does not equal $60M a year plus the $30M retention pool; we quote the filing's own total.

More at https://www.techarcade.io

#techarcade #AI #Disney #presbyopia #technews